Fc γ receptor IIB (FcγRIIB) is an inhibitory molecule capable of reducing antibody immunotherapy efficacy. We hypothesized its expression could confer resistance in patients with diffuse large B-cell lymphoma (DLBCL) treated with anti-CD20 monoclonal antibody (mAb) chemoimmunotherapy, with outcomes varying depending on mAb (rituximab [R]/obinutuzumab [G]) because of different mechanisms of action. We evaluated correlates between FCGR2B messenger RNA and/or FcγRIIB protein expression and outcomes in 3 de novo DLBCL discovery cohorts treated with R plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reported by Arthur, Schmitz, and Reddy, and R-CHOP/G-CHOP-treated patients in the GOYA trial (NCT01287741). In the discovery cohorts, higher FCGR2B expression was associated with significantly shorter progression-free survival (PFS; Arthur: hazard ratio [HR], 1.09; 95% confidence interval [CI], 1.01-1.19; P = .0360; Schmitz: HR, 1.13; 95% CI, 1.02-1.26; P = .0243). Similar results were observed in GOYA with R-CHOP (HR, 1.26; 95% CI, 1.00-1.58; P = .0455), but not G-CHOP (HR, 0.91; 95% CI, 0.69-1.20; P = .50). A nonsignificant trend that high FCGR2B expression favored G-CHOP over R-CHOP was observed (HR, 0.67; 95% CI, 0.44-1.02; P = .0622); however, low FCGR2B expression favored R-CHOP (HR, 1.58; 95% CI, 1.00-2.50; P = .0503). In Arthur and GOYA, FCGR2B expression was associated with tumor FcγRIIB expression; correlating with shorter PFS for R-CHOP (HR, 2.17; 95% CI, 1.04-4.50; P = .0378), but not G-CHOP (HR, 1.37; 95% CI, 0.66-2.87; P = .3997). This effect was independent of established prognostic biomarkers. High FcγRIIB/FCGR2B expression has prognostic value in R-treated patients with DLBCL and may confer differential responsiveness to R-CHOP/G-CHOP.

1st Medical Faculty Charles University Prague Czech Republic; and

Antibody and Vaccine Group Centre for Cancer Immunology School of Cancer Sciences University of Southampton Faculty of Medicine Southampton United Kingdom

BC Cancer Centre for Lymphoid Cancer Vancouver BC Canada

Canada's Michael Smith Genome Sciences Centre Vancouver BC Canada

Department of Hematopathology University of Schleswig Holstein Campus Kiel Kiel Germany

Department of Medicine University of British Columbia Vancouver BC Canada

Department of Molecular Biology and Biochemistry Simon Fraser University Burnaby BC Canada; and

Department of Translational and Precision Medicine Hematology Sapienza University Rome Italy

F Hoffmann La Roche Ltd Basel Switzerland

Genentech Inc South San Francisco CA

Multidisciplinary Oncology Outpatient Clinic Candiolo Cancer Institute FPO IRCCS Candiolo Italy

Roche Innovation Center Zurich Schlieren Switzerland

Royal Marsden Hospital Sutton United Kingdom

School of Cancer Sciences University of Southampton Southampton United Kingdom

Southampton University Hospitals NHS Foundation Trust Southampton United Kingdom

St James's Institute of Oncology Leeds United Kingdom

See more in PubMed

Edwards JC, Cambridge G.. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol. 2006;6(5):394-403. PubMed

Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica. 2010;95(1):135-143. PubMed PMC

Marshall MJE, Stopforth RJ, Cragg MS. Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunol. 2017;8:1245. PubMed PMC

Sopp J, Cragg MS. Deleting malignant B cells with second-generation anti-CD20 antibodies. J Clin Oncol. 2018;36(22):2323-2325. PubMed

Uchida J, Hamaguchi Y, Oliver JA, et al. . The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199(12):1659-1669. PubMed PMC

Minard-Colin V, Xiu Y, Poe JC, et al. . Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood. 2008;112(4):1205-1213. PubMed PMC

Beers SA, French RR, Chan HT, et al. . Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115(25):5191-5201. PubMed

Tipton TR, Roghanian A, Oldham RJ, et al. . Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood. 2015;125(12):1901-1909. PubMed

Gül N, Babes L, Siegmund K, et al. . Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest. 2014;124(2):812-823. PubMed PMC

Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42(6):717-727. PubMed

Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013;35(5):585-600. PubMed

Lehmann B, Biburger M, Brückner C, et al. . Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response. Sci Immunol. 2017;2(7):eaah6413. PubMed

McCord R, Bolen CR, Koeppen H, et al. . PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv. 2019;3(4):531-540. PubMed PMC

Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34-47. PubMed

Burgess M, Mapp S, Mazzieri R, et al. . Increased FcγRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients. Oncogene. 2017;36(17):2366-2376. PubMed

Klanova M, Oestergaard MZ, Trněný M, et al. . Prognostic impact of natural killer cell count in follicular lymphoma and diffuse large B-cell lymphoma patients treated with immunochemotherapy. Clin Cancer Res. 2019;25(15):4634-4643. PubMed

Pawluczkowycz AW, Beurskens FJ, Beum PV, et al. . Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009;183(1):749-758. PubMed

van Imhoff GW, McMillan A, Matasar MJ, et al. . Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017;35(5):544-551. PubMed

Maloney DG, Ogura M, Fukuhara N, et al. . A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. Blood Adv. 2020;4(16):3886-3893. PubMed PMC

Goede V, Fischer K, Busch R, et al. . Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-1110. PubMed

Hiddemann W, Barbui AM, Canales MA, et al. . Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety [published correction appears in J Clin Oncol. 2018;36(27):2815]. J Clin Oncol. 2018;36(23):2395-2404. PubMed

Marcus R, Davies A, Ando K, et al. . Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331-1344. PubMed

Vitolo U, Trněný M, Belada D, et al. . Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529-3537. PubMed

Sehn LH, Martelli M, Trněný M, et al. . Final analysis of GOYA: a randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2019;134(suppl 1):4088. PubMed PMC

Cragg MS, Morgan SM, Chan HT, et al. . Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045-1052. PubMed

Teeling JL, French RR, Cragg MS, et al. . Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104(6):1793-1800. PubMed

Ivanov A, Beers SA, Walshe CA, et al. . Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009;119(8):2143-2159. PubMed PMC

Alduaij W, Ivanov A, Honeychurch J, et al. . Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117(17):4519-4529. PubMed PMC

Herter S, Herting F, Mundigl O, et al. . Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12(10):2031-2042. PubMed

Mössner E, Brünker P, Moser S, et al. . Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-4402. PubMed PMC

Lim SH, Vaughan AT, Ashton-Key M, et al. . Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood. 2011;118(9):2530-2540. PubMed

Elias S, Kahlon S, Kotzur R, Kaynan N, Mandelboim O. Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL). OncoImmunology. 2018;7(6):e1428158. PubMed PMC

Vaughan AT, Iriyama C, Beers SA, et al. . Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood. 2014;123(5):669-677. PubMed

Arthur SE, Jiang A, Grande BM, et al. . Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat Commun. 2018;9(1):4001. PubMed PMC

Schmitz R, Wright GW, Huang DW, et al. . Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396-1407. PubMed PMC

Reddy A, Zhang J, Davis NS, et al. . Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481-494.e15. PubMed PMC

Dobin A, Davis CA, Schlesinger F, et al. . STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21. PubMed PMC

Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923-930. PubMed

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. PubMed PMC

Ennishi D, Jiang A, Boyle M, et al. . Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(3):190-201. PubMed PMC

Tsuyama N, Sakata S, Baba S, et al. . BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood. 2017;130(4):489-500. PubMed

Lee CS, Ashton-Key M, Cogliatti S, et al. . Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98). Br J Haematol. 2015;168(1):145-148. PubMed

Roghanian A, Teige I, Mårtensson L, et al. . Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer Cell. 2015;27(4):473-488. PubMed

See more in PubMed

ClinicalTrials.gov
NCT01287741